![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
1. A sensitive method for the determination of 3-(4-cyano-2-oxobutylidene amino)-2-oxazolidone, the open-chain cyano-derivative of the veterinary drug furazolidone, in swine plasma and tissues is described.
2. After dosing adult swine orally with furazolidone (690 mg animal per day) for 10 days no furazolidone was detected in liver, kidney and muscle (< 2 ng/g). The half life of furazolidone as measured from the terminal phase of the plasma curves was 45 minutes. In urine, small amounts (<0.3% of total dose) of furazolidone were detected.
3. In contrast to other animals, 3-(4-cyano-2-oxobutylidene amino)-2-oxazolidone is a minor metabolite in swine with a plasma half life of 4h. No cyano-derivative was detected in liver and kidney (< 5 ng/g) 2 h after the last administration of furazolidone; 24 h after the last administration, the concentration in plasma was <2 ng/ml and in muscle <5/g.
4. The cyano-derivative was not mutagenic in the Salmonella microsome test, with or without metabolic activation.
